REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 12th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionThis Registration Rights Agreement (this “Agreement”) is made as of December 23, 2019, by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
WARRANT AMENDMENT AGREEMENTWarrant Amendment Agreement • March 12th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionThis Warrant Amendment Agreement (this “Agreement”), dated as of December 23, 2019 (the “Effective Date”), by and between Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities list on Schedule I hereto, as the Requisite Holders (as defined below). All capitalized terms used in this Agreement but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Warrants (as defined below).
SECOND AMENDMENT TO LEASELease • March 12th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionTHIS SECOND AMENDMENT TO LEASE (“Amendment”) is made this 13th day of January, 2020 by and between 505 EAGLEVIEW BOULEVARD ASSOCIATES, a Pennsylvania limited partnership (“Landlord”) and IDERA PHARMACEUTICALS, INC., a corporation (“Tenant”).
VOTING AGREEMENTVoting Agreement • March 12th, 2020 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 12th, 2020 Company Industry JurisdictionTHIS VOTING AGREEMENT (this “Agreement”) is entered into as of December 23, 2019, by and among the investors who are signatories hereto (each, an “Investor” and collectively, the “Investors”) and Idera Pharmaceuticals, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein but not otherwise defined shall have the meaning given to them in the Purchase Agreement (as defined below).